BlueLight Therapeutics

BlueLight Therapeutics is a private biotechnology company developing small molecule therapeutics for difficult-to-drug targets using a proprietary structure-driven discovery platform. Formerly known as Biodesy, the company changed its name to BlueLight Therapeutics in May 2020 to reflect its shift from biomolecular characterization toward therapeutics discovery and development. Its core platform uses Second Harmonic Generation (SHG) technology to measure real-time conformational changes in biomolecules and identify progressable chemical matter that may be missed by traditional screening methods. The company has stated an initial focus on oncology while positioning its platform for broader application across serious diseases. Publicly available information suggests BlueLight remains an early-stage, platform-oriented drug discovery company rather than a clinical-stage developer.